v3.26.1
Segment Information - Schedule of Financial Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Feb. 28, 2026
Mar. 31, 2026
Mar. 31, 2025
Operating Expenses:      
Research and development   $ 1,204 $ 2,602
General and administrative   3,738 3,245
Operating loss   (4,942) (5,847)
Other income, net   (54) (105)
Benefit from income taxes $ 387 (387) (962)
Net loss   (4,489) (4,724)
Reportable Segment      
Operating Expenses:      
Research and development   1,204 2,602
General and administrative   3,738 3,245
Investor relations/public relations/communications   237 331
Finance   585 629
Legal   1,094 224
Business development   149 127
Share based compensation expense   293 404
Other   47 386
Operating loss   (4,942) (5,847)
Other income, net   66 161
Benefit from income taxes   (387) (962)
Net loss   (4,489) (4,724)
Cash and marketable securities   13,060 25,833
Reportable Segment | Corporate      
Operating Expenses:      
General and administrative   1,333 1,144
Reportable Segment | BOLSTER trial      
Operating Expenses:      
Research and development   (50) 788
Reportable Segment | ASCEND trial      
Operating Expenses:      
Research and development   174 21
Reportable Segment | Chemistry, manufacturing and controls      
Operating Expenses:      
Research and development   191 220
Reportable Segment | Clinical department      
Operating Expenses:      
Research and development   768 1,156
Reportable Segment | Other      
Operating Expenses:      
Research and development   $ 121 $ 417